<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100881">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791244</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200136-560</org_study_id>
    <secondary_id>2012-004887-22</secondary_id>
    <nct_id>NCT01791244</nct_id>
  </id_info>
  <brief_title>A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device</brief_title>
  <acronym>RebiQoL</acronym>
  <official_title>A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      This is a randomized, comparative, and multicenter study to assess the impact of a patient
      support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in
      subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™
      device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) psychological score at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) psychological score at Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) total score at Month 6 and 12</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Euro Quality of Life Questionnaire with 5 questions alternatives (EQ5D-5L) score at Month 6 and 12</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with treatment adherence</measure>
    <time_frame>Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fatigue Severity Scale score and Modified Fatigue Impact Scale score at Month 6 and 12</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hospital Anxiety and Depression Scale score at Month 6 and 12</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Working ability per subject at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Adverse events</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with categorical score on subject satisfaction questionnaire</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of health care personnel with categorical score on Health Care Personnel satisfaction questionnaire</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lifestyle questionnaire score in subjects receiving Min Support Plus at Month 6 and 12</measure>
    <time_frame>Baseline, Month 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Lifestyle goals score in subjects receiving Min Support Plus</measure>
    <time_frame>Baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economy as assessed by Quality of life questionnaire</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Technical support for the RebiSmart™ device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient support program (MinSupport Plus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Technical support for the RebiSmart™ device</intervention_name>
    <description>Rebif® will be administered by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) three times a week in accordance to the summary of product characteristics. Subjects will receive only technical support for the RebiSmart™ device.</description>
    <arm_group_label>Technical support for the RebiSmart™ device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient support program (MinSupport Plus)</intervention_name>
    <description>Rebif® will be administered by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) three times a week in accordance to the summary of product characteristics. Subjects will receive support program (MinSupport Plus) which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.</description>
    <arm_group_label>Patient support program (MinSupport Plus)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 or older

          -  A diagnosis of relapsing-remitting multiple sclerosis according to the revised
             McDonald Criteria (2010)

          -  Treatment with Rebif® 22 or 44 mcg subcutaneously three times a week in accordance to
             the Summary of product characteristics

          -  Rebif® administered by the RebiSmart™ device

          -  Provided a signed informed consent form

        Exclusion Criteria:

          -  Has received any components, except for technical support, of MinSupport Plus prior
             to study entry

          -  Has difficulty reading and/or understanding Swedish

          -  Has a mental condition rendering the subject unable to understand the nature, scope
             and possible consequences of the study, and/or evidence of an uncooperative attitude

          -  No access to computer

          -  Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Please contact the Merck Communications Service for Recruiting locations</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Angered</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danderyd</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eksjö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>KS Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmö/Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Motala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trollhättan</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ängelholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Örnsköldsvik</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 2, 2016</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing-Remitting</keyword>
  <keyword>Rebif</keyword>
  <keyword>RebiSmart</keyword>
  <keyword>Patient support program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
